{"id":"NCT02750306","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)","officialTitle":"A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-23","primaryCompletion":"2018-09-30","completion":"2018-09-30","firstPosted":"2016-04-25","resultsPosted":"2019-10-16","lastUpdate":"2019-10-16"},"enrollment":285,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Sleep Initiation and Maintenance Disorders","Alzheimer Disease"],"interventions":[{"type":"DRUG","name":"Suvorexant","otherNames":["MK-4305"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Suvorexant","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study aims to examine the safety and efficacy of suvorexant (MK-4305) to improve sleep in individuals with Alzheimer's disease (AD). The primary hypothesis for the study is that suvorexant is superior to placebo in improving insomnia as measured by change from baseline in polysomnography (PSG)-derived total sleep time (TST) at Week 4.","primaryOutcome":{"measure":"Change From Baseline in Polysomnography-derived Total Sleep Time (TST) at Week 4","timeFrame":"Baseline and Week 4","effectByArm":[{"arm":"Suvorexant","deltaMin":73.4,"sd":null},{"arm":"Placebo","deltaMin":45.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00128"}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":19,"exclusionCount":41},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["36529106","33189083","31944580"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":142},"commonTop":[]}}